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Background: The pathogenesis of multiple myeloma involves complex genetic and epigenetic events. This study
aimed to investigate the role and clinical relevance of the long non-coding RNA (lncRNA), metastasis-associated
lung adenocarcinoma transcript 1 (MALAT1) in multiple myeloma.
Methods: Bone marrow mononuclear cells were collected for analysis. The samples of multiple myeloma were taken
from 45 patients at diagnosis, 61 post-treatment, and 18 who relapsed or had progression. Control samples were
collected from 20 healthy individuals. Real-time quantitative reverse transcription polymerase chain reactions were
performed to evaluate the expression of MALAT1. The clinical relevance of MALAT1 expression was also explored.
Results: MALAT1 was overexpressed in the newly diagnosed patients compared with post-treatment patients
(mean ΔCT: -5.54 ± 0.16 vs. -3.84 ± 0.09, 3.25-fold change; p < 0.001) and healthy individuals (mean ΔCT: -5.54 ± 0.16
vs. -3.95 ± 0.21, 3.01-fold change; p < 0.001). The expression of MALAT1 strongly correlated with disease status, and the
magnitude of change in MALAT1 post-treatment had prognostic relevance. The patients with early progression had
a significantly smaller change in MALAT1 after treatment (mean ΔCT change: 1.26 ± 1.06 vs. 2.09 ± 0.79, p = 0.011). A
cut-off value of the change in MALAT1 (ΔCT change: 1.5) was obtained, and the patients with a greater decrease in
MALAT1 (difference in ΔCT >1.5) had significantly longer progression-free survival compared with the patients with a
smaller MALAT1 change (24 months vs. 11 months; p = 0.001). For the post-treatment patients, the risk of early
progression could be predicted using this cut-off value.
Conclusions: MALAT1 was overexpressed in patients with myeloma and may play a role in its pathogenesis. In addition,
MALAT1 may serve as a molecular predictor of early progression.
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Multiple myeloma is a hematological malignancy cha-
racterized by abnormal proliferation of monoclonal
plasma cells in bone marrow leading to various end-organ
damage including anemia, hypercalcemia, renal insufficiency
and osteolytic bone disease [1]. The development of
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With the progression from monoclonal gammopathy
of undetermined clinical significance to myeloma, several
complex genetic events are involved including cytogenetic
abnormalities, primary or secondary chromosomal
translocation, and activation of oncogenes. These oncoge-
netic events include dysregulation of the cyclin D gene,
mutation of KRAS or NRAS, and constitutively activated
nuclear factor κB (NFκB) pathway [4-7]. In addition, the
bone marrow microenvironment has also been reported
to play an important role in the pathogenesis of this
disease [8-10].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of the human genome is actively transcribed to RNA,
but less than 2% of RNA encodes proteins [11,12].
Non-coding RNAs (ncRNAs) are a class of RNA with
little or no capacity for protein synthesis that includes
small ncRNAs and long ncRNAs (lncRNAs), which
have a length of more than 200 nucleotides. The lncRNAs
have been highly conserved throughout mammalian
evolution including in humans, and they have been shown
to be aberrantly expressed in cancer tissue and to be
involved in oncogenic or tumor suppressive processes [13].
Metastasis-associated lung adenocarcinoma transcript 1
(MALAT1) is one of the few biologically well-studied
lncRNAs, and is located on chromosome 11 (11q13.1).
This lncRNA is highly conserved in mammals and is more
than 8000 nucleotides in length [14-16]. MALAT1 has
been shown to expressed in numerous tissues including
the central nervous, endocrine, immune, reproductive and
lymphoid systems [17,18]. With respect to its function,
MALAT1 is localized to nuclear speckles and has
been associated with regulation of gene expressions
[19,20]. In addition, MALAT1 may play a role in the
regulation of alternative splicing and cell cycle [21-23]. In
terms of its association with cancer, MALAT1 has been
shown to be oncogenic and to be overexpressed in
several solid tumors including lung, colorectal, bladder
and laryngeal cancers [24-27].
The association between lncRNAs and multiple
myeloma remains undetermined, and related studies
are lacking. It has been reported that deregulation of the
cell cycle is an important event during carcinogenesis, and
that this event is also associated with MALAT1 [23].
MALAT1 has also been reported to be expressed broadly
in human tissues including lymphoid tissues, bone
marrow and B lymphocytes [28,29]. Taken together,
we hypothesized that MALAT1 may play a role in
multiple myeloma. Therefore, the aim of the present
study was to evaluate the expression of MALAT1 in
bone marrow mononuclear cells from patients with
multiple myeloma and with different disease status
and healthy individuals.
Methods
Multiple myeloma patients and samples
The study cohort included adult patients (aged 20 years
and older) with multiple myeloma diagnosed at Kaohsiung
Medical University Hospital from 2007 to 2012 who
were free from other coexisting malignant diseases.
The diagnosis of multiple myeloma was confirmed by
bone marrow analysis which revealed a monoclonal
plasma cell count over 10% by definition and related
laboratory tests. The patients of extramedullary myeloma
were not enrolled to this study. The diagnostic criteria,
disease status and response to treatment were based onthe criteria of the International Myeloma Working Group
[17-19]. Forty-five samples were collected from newly
diagnosed patients (29 males, 16 females; median age
62.3 years, range 49 to 79 years) with different subtypes
(IgG: 21, IgA: 13, light chain: 11) and clinical stages
(Durie-Salmon stage 1: 1, stage 2: 6, stage 3: 38 or
international staging system stage 1: 7, stage 2: 17,
stage 3: 21). In addition, 61 samples were collected
from patients after myeloma treatment, and 18 samples
from patients who had experienced disease progression or
relapse. The disease status of the post-treatment patients
was mainly a complete response (CR) and very good
partial response (VGPR) based on the criteria of
International Myeloma Working Group. In addition, the
percentage of plasma cells in the patients achieving VGPR
or CR after treatment was less than 5%.
We also enrolled 20 healthy and genetically unrelated
Taiwanese volunteers (healthy individuals) as the control
group. These healthy individuals had undergone bone
marrow analysis to investigate cytopenia that had been
noted in blood tests, but whose bone marrow examinations
revealed no abnormalities. All patients and healthy
individuals signed informed consent forms after the
study had been thoroughly explained.
The research protocol was created in accordance with
the Declaration of Helsinki, and it was reviewed, approved
and registered by the Ethics Committee of Kaohsiung
Medical University Hospital (KMUHIRB-2012-01-08(II)).
RNA extraction and reverse transcription
Bone marrow mononuclear cells were isolated for this
study. First, the bone marrow samples were collected in
tubes containing ethylenediaminetetraacetic acid (EDTA),
preserved at 4°C and processed within 4 hours of collection.
The bone marrow samples were then centrifuged at
12,000 × g for 15 minutes, after which ammonium chloride
lysis buffer (10 mM NH4Cl, 10 mM KHCO3, 0.1 mM
EDTA) was used to clear the red blood cells and effectively
isolate the fraction of mononuclear cells.
The isolated bone marrow samples were stored at -80°C
until RNA extraction. Isolation of RNA from 200 μL of
cell suspension was carried out using the TRIzol protocol
(Invitrogen). The extracted RNA was then treated with
DNase (Promega) and the concentration was determined
by spectrophotometric OD260 measurement. The integrity
of the RNA was examined by 1.2% RNA denaturing agarose
gel electrophoresis.
Reverse transcription was performed to generate
complementary DNA in a final volume of 20 μL, containing
2 μg RNA, 25X dNTP mix (100 mM), 10X random primer
(0.5 μM), RNase inhibiter, reverse transcriptase, reverse
transcriptase buffer (10X) and diethylpyrocarbonate (DEPC)-
treated water. The procedure was performed according to
the manufacturer’s protocol (Applied Biosystems).
Table 1 Expression of MALAT1 in patients with multiple
myeloma and healthy individuals
Population No. Expression of MALAT1
(Mean ΔCT)
Newly diagnosed 45 -5.54 ± 0.16
Post-treatment 61 -3.84 ± 0.09
Relapse or progression 18 -4.92 ± 0.23
Healthy individuals 20 -3.95 ± 0.21













The 61 post-treatment samples were composed of 58 samples collected in
disease status of VGPR or CR from 42 patients. The percentages of plasma cells
were all less than 5%.
The 3 samples collected at a disease status of partial response came from
3 patients.
Note:
ΔCT = CT (MALAT1 - GAPDH).
Increased expression (fold change) was calculated as 2-ΔΔCT.
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chain reaction (RT-PCR) analysis of MALAT1 expression
Real-time quantitative RT-PCR was performed in a final
volume of 10 μL containing 1 μL of RT product, 0.6 μL
of primer (Roche), 1.2 μL of probe (Roche, cat. no.
04688945001), 2.2 μL of DEPC H2O and 5 μL of qPCR
Master Mix (2X) (KAPA Biosystem, KK 4600). Analysis of
the human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene was used as the internal control.
The primer sequences of MALAT1 were as follows:
forward, 5’-GACCCTTCACCCCTCACC-3’; reverse,
5’-TTATGGATCATGCCCACAAG-3’, and the primer
sequences of GAPDH were as follows: forward, 5’-
AAAGTCCGCCATTTTGCCACT-3’; and reverse,
5’-CCAAATCGTTAGCGCTCCTT-3’.
Real-time quantitative RT-PCR was performed in a
LightCycler 480 Real-Time PCR System (Roche). The
PCR cycling program consisted of incubation for enzyme
activation at 95°C for 10 minutes, followed by melting at
95°C for 10 seconds, annealing at 60°C for 30 seconds,
and then extension at 72°C for 1 second, for a total of
50 cycles.
The expression levels of MALAT1 were normalized to
the internal control GAPDH reference to obtain the
relative threshold cycle (ΔCT). The relative expression
levels were calculated by the comparative CT (ΔΔCT)
method, and relative expression folds (2−ΔΔCT) were
calculated.
Statistical analysis
The independent two samples t-test was used to compare
the expression levels of MALAT1 in the different
subgroups. The frequency between each categorical
variable was compared by the chi-square test (χ2 test),
with Yates correction or Fisher’s exact test. Analysis of
correlation was performed using Pearson correlations or
Spearman correlation coefficients. Receiver operating
characteristic (ROC) analysis was used to evaluate the
cut-off value. Survival curves were plotted using the
Kaplan–Meier method and compared using the log-rank
test. Relative risk analysis was performed by calculating
the odds ratio (OR) and 95% confidence interval (CI) by
Cox regression analysis.
All statistical analyses were based on two-sided
hypothesis tests with a significance level of p < 0.05. The
analyses were performed using SPSS version 17.0 (SPSS,
Chicago, IL, USA).
Results
Correlation of MALAT1 expression with disease status in
multiple myeloma
The expression of MALAT1 was significantly higher in
the patients at diagnosis compared with the patients
post-treatment (mean ΔCT: -5.54 ± 0.16 vs. -3.84 ± 0.09,3.25-fold change; p < 0.001) or the healthy individuals
(mean ΔCT: -5.54 ± 0.16 vs. -3.95 ± 0.21, 3.01-fold change;
p < 0.001) (Table 1). This suggests that MALAT1 may be
deregulated and overexpressed in patients with multiple
myeloma.
The association of MALAT1 expression pattern with
disease status was further analyzed. The expression of
MALAT1 was found to be significantly decreased in the
post-treatment patients to a level that was similar to
that of the healthy individuals (mean ΔCT: -3.84 ± 0.09
vs. -3.95 ± 0.21, p = 0.614). In addition, in the patients in
whom the disease had progressed or relapsed, the expres-
sion of MALAT1 was significantly increased compared
with the post-treatment patients (mean ΔCT: -4.92 ± 0.23
vs. -3.84 ± 0.09, 1.89-fold change; p < 0.001) (Table 1). For
the patients who underwent multiple bone marrow
examinations during treatment and follow-up, the expres-
sion of MALAT1 changed dynamically and was correlated
with disease status (Figure 1).
Association between MALAT1 expression and clinical
outcome
The clinical relevance of MALAT1 was analyzed. The
expressions of MALAT1 in the 45 newly diagnosed
patients with different clinical characteristics were
listed in Additional file 1: Table S1. We noticed that
the expression of MALAT1 was not associated with the
percentage of plasma cells in the bone marrow (r = -0.037,
p = 0.808) (Additional file 2: Table S2). With regards to the
association between MALAT1 expression and prognosis,
Figure 1 Expression of MALAT1 during treatment and follow-up
in two representative patients. The first patient (Patient 1) had a
high expression of MALAT1 initially, which then decreased after
successful induction chemotherapy and autologous peripheral blood
stem cell transplantation, 9 months after the time of diagnosis. At
18 months, disease relapse was accompanied by an increase in
MALAT1 expression. After salvage treatment, the disease was
controlled and the expression of MALAT1 decreased. Eventually, the
disease progressed and the expression of MALAT1 increased. The
second patient (Patient 2) received induction chemotherapy
followed by peripheral blood stem cell transplantation. The
expression of MALAT1 decreased markedly after the treatment
achieved complete remission. The disease status remained in
remission during the follow-up period and was accompanied by a
low expression of MALAT1.
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expression level (Cut-off value: ΔCT = -5.30) determined
by ROC analysis was not associated with inferior
prognosis including progression-free survival (PFS)
(median PFS: 21.0 ± 9.9 vs. 15.0 ± 6.0 months, p = 0.390)
or overall survival (OS) (median OS: Not reached;
mean OS: 31.9 ± 4.3 vs. 37.8 ± 3.6 months, p = 0.172)
(Additional file 3: Figure S1). However, we hypothesized
the magnitude of the change (decrease) after myeloma-
related therapy may have been related to the degree of
treatment response and prognosis, because the expression
ofMALAT1 changed after treatment.
Among the 45 patients, 36 (including 21 men) with a
mean age of 61.3 years received bone marrow examinations
at least twice including at diagnosis and after treatment,
and hence the expression of MALAT1 was available for
further analysis. The median PFS of these 36 patients was
18 months (95% CI 8.95-25.35), and we used this median
PFS as a cut-off value to divide the patients into two groups
of early (PFS ≤18 months) or late (PFS >18 months)
progression, with 18 patients in each group. We found that
the only parameter which showed a significant difference
between these two groups was the magnitude of MALAT1
change after treatment. The patients with early progression
had a significantly smaller magnitude of MALAT1
change after treatment compared with the patients withlate progression (mean difference of ΔCT: 1.26 ± 1.06 vs.
2.09 ± 0.79; p = 0.011) (Table 2).
Role of MALAT1 in predicting early progression
The previous results showed that the magnitude of
MALAT1 change (as quantified by the difference in ΔCT)
was the only parameter associated with PFS. We then used
ROC analysis and obtained a cut-off expression change
value of 1.5 (post-treatment ΔCT – pre-treatment ΔCT;
approximately a 2.8-fold change) with an estimated area
under the ROC curve of 0.79 (p = 0.003). The proportion
of patients with a lower MALAT1 change (difference in
ΔCT ≤1.5) was significantly higher in those who displayed
early progression (n = 13, 72.2%) compared with those who
displayed late progression (n = 4, 22.2%; p = 0.007).
In terms of an association between clinical characteristics
and magnitude of MALAT1 change, the patients with
greater changes (difference in ΔCT >1.5) may have had a
better treatment response (Additional file 4: Table S3). The
PFS and OS rates were also analyzed using the cut-off value
from ROC analysis. With a minimum follow-up period of
12 months (range: 12 to 48 months), the patients with a
greater MALAT1 decrease (difference in ΔCT >1.5) had a
significantly prolonged median PFS (24 months, range
11-48 months) compared with the patients with a
smallerMALAT1 change (11 months, range: 6-21 months;
p = 0.001). There was no significant difference in OS
between the two groups (median OS: Not reached;
mean OS: 39.2 ± 3.6 months, range: 12-48 months vs.
32.8 ± 4.2 months, range: 12-48 months; p = 0.313)
(Figure 2).
Cox regression analysis was used to identify the relative
risk of early progression, which revealed that autologous
hematopoietic stem cell transplantation (Auto-HSCT) and
the magnitude of MALAT1 change were significantly asso-
ciated with the prognosis. For all post-treatment patients
(n = 36), those with a smaller MALAT1 change (difference
in ΔCT ≤1.5) had a significantly higher risk of early progres-
sion of disease (OR 4.89, 95% CI 1.73-13.86; p = 0.003),
while auto-HSCT reduced the risk of early progression (OR
0.22, 95% CI 0.05-0.97; p = 0.046). For the post-treatment
patients with a VGPR or CR (n = 33), a smaller MALAT1
change (difference in ΔCT ≤1.5) remained the single
factor predictive of early progression of multiple myeloma
(OR 4.38, 95% CI 1.48-12.99; p = 0.008) (Table 3). Using
the cut-off value to predict the patients who would
show early progression (PFS ≤18 months), the estimated
accuracy was 75% with a sensitivity of 72.2%, a specificity of
77.8%, a positive predictive value of 76.5%, and a negative
predictive value of 73.7%.
Discussion
In the current study, we demonstrated that MALAT1
was overexpressed in the patients with newly diagnosed
Table 2 The clinical characteristics of patients with early (PFS ≤18 months) or late (PFS >18 months) progression
All patients
(N = 36)
PFS ≤ 18 months
(N = 18)
PFS > 18 months
(N = 18)
P value
Age (years, mean(SD)) 61.3(8.3) 61.9 ± 7.8 60.6 ± 8.7 0.633
Male, n (%) 21(58.3%) 10(55.6%) 11(61.1%) 1.000
M protein 0.210
IgG, n (%) 19(52.8%) 7(38.9%) 12(66.6%)
IgA, n (%) 10(27.8%) 7(38.9%) 3(16.7%)
Light chain, n (%) 7(19.4%) 4(22.2%) 3(16.7%)
International staging system 0.881
Stage 1, n (%) 5(13.9%) 2(11.1%) 3(16.7%)
Stage 2, n (%) 12(33.3%) 6(33.3%) 6(33.3%)
Stage 3, n (%) 19(52.8%) 10(55.6%) 9(50%)
Durie-Salmon stage 1.000
Stage 1, n (%) 0 0 0
Stage 2, n (%) 5(13.9%) 2(11.1%) 3(16.7%)
Stage 3, n (%) 31(86.1%) 16(88.9%) 15(83.3%)
Percentage of plasma cell in bone marrow (%, mean (SD)) 50.8 ± 25.3 54.3 ± 26.8 47.3 ± 23.8 0.740
Anemia, n (%) 27(75%) 14(77.8%) 13(72.2%) 1.000
Renal insufficiency, n (%) 9(25%) 5(27.8%) 4(22.2%) 1.000
Hypercalcemia, n (%) 14(38.9%) 8(44.4%) 6(33.3%) 0.733
Bone disease, n (%) 25(69.4%) 14(77.8%) 11(61.1%) 0.471
Cytogenetic abnormality, n (%) 7(19.4%) 3(16.7%) 4(22.2%) 1.000
Bortezomib-containing induction Tx, n (%) 11(30.6%) 4(22.2%) 7(38.9%) 0.471
Auto-HSCT in 1st fine Tx, n (%) 9(25%) 2(11.1%) 7(38.9%) 0.121
Treatment response:
CR, n (%) 7(19.4%) 1(5.6%) 6(33.3%) 0.088
VGPR, n (%) 26(72.2%) 14(77.8%) 12(66.7%) 0.711
PR, n (%) 3(8.3%) 3(16.7%) 0 0.229
Expression of MALAT1 at diagnosis (Mean ΔCT ± SD) -5.52 ± 1.15 -5.77 ± 0.89 0.353
Magnitude of MALAT1 change after treatment (Difference in ΔCT) 1.26 ± 1.06 2.09 ± 0.79 0.011
Difference in ΔCT = ΔCT (Post-treatment - newly diagnosed).
Auto-HSCT, autologous hematopoietic stem cell transplantation; CR, complete response; VGPR, very good partial response; PFS, progression-free survival;
Tx, treatment.
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may play a role in multiple myeloma.
The results of the present study are in contrast with
the study by Isin et al., in which the expression of
MALAT1 was found to be significantly lower in patients
with multiple myeloma [30]. A possible explanation for
this discrepancy may be due to different sample sources.
Our study analyzed the expression of MALAT1 in bone
marrow mononuclear cells rather than plasma samples,
because the pathogenesis of myeloma is closely related
to bone marrow. Another possible explanation for the
higher expression of MALAT1 in the current study may
be associated with the bone marrow microenvironment
which supports the proliferation of myeloma cells. In
addition, our analysis revealed that expression ofMALAT1in newly diagnosed myeloma patients is not associated
with the total percentage of plasma cells in the bone
marrow. This finding indicated that the expression of
MALAT1 may be associated with interactions between
myeloma cells and the bone marrow microenviron-
ment. The detailed mechanism needs further studies
to elucidate.
The current study also investigated the clinical rele-
vance of MALAT1 in patients with multiple myeloma.
We found that the expression of MALAT1 changed
dynamically when stratified by disease status. In addition,
the major clinical significance was the magnitude of change
in expression after treatment rather than the initial
expression. This finding is different from previous studies of
solid tumors which have reported that a higher expression
Figure 2 Kaplan-Meier estimates of the probability of
progression-free survival (PFS, A) and overall survival (OS, B)
are shown according to the magnitude in the change of
MALAT1 expression after treatment. The patients were divided
into two groups by a cut-off value (difference in ΔCT: 1.5).
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patients with a greater decrease in MALAT1 after initial
treatment had a significantly prolonged PFS, which is
consistent with the current consensus that therapeutic
intervention to achieve a maximal response is beneficial
for patients with multiple myeloma [31,32]. In terms of OS,Table 3 Multivariate Cox regression analysis for all post-treat
treatment response of VGPR/CR
PFS ≤
(
All patients (N = 36) Auto-HSCT in 1st line treatment, n 9 2




Auto-HSCT in 1st line treatment, n 9 2
Difference in △CT ≤1.5, n 14 10
OR, Odds ratio; CI, confidential interval; Auto-HSCT, autologous hematopoietic stem
PFS, progression-free survival.we did not find a significant benefit in the post-treatment
patients with a greater decrease in MALAT1. A possible
explanation may be the incorporation of potent and effect-
ive salvage treatment in the patients who experienced a
relapse or progression of disease, as well as the fact that
some patients received auto-HSCTafter salvage treatment.
We also found that MALAT1 may serve as a marker
to predict early progression. Because the duration of
response decreases with an increasing number of salvage
regimens after progression, identification of patients at
risk of early progression after first-line treatment is an
important issue. More intensive treatment may improve
the prognosis in this subgroup. We also found that
patients with a smaller MALAT1 change after treatment
had a significantly higher risk for early progression, even
in those with a VGPR, CR and normal percentage of
plasma cells in bone marrow. This finding suggests that
the expression of MALAT1 can be used to identify the
patients at risk of early progression. Accordingly, the
therapeutic strategy may be adjusted to be initially more
aggressive, as more potent treatment may reduce the
risk of early progression and prolong PFS.
Our findings may provide a new insight into the pathogen-
esis of multiple myeloma. However, there are some limita-
tions to this study. First, the cytogenetic examinations were
done by conventional G-band metaphase chromosome ana-
lysis, and the percentage of cytogenetic abnormalities was
relative low. Therefore, the association between MALAT1
and specific cytogenetic abnormalities remains to be deter-
mined. Further analysis by fluorescent in-situ hybridization
with larger cohort may provide more impactful insight on
the clinical relevance of MALAT1 expression in multiple
myeloma. Second, we didn’t evaluate the expression of
MALAT1 in patients resistant to myeloma therapy due to
no available samples. Third, the number of cases to evaluate
the clinical relevance of MALAT1 was limited, which was
likely due to the stringency of the enrollment criteria.
Conclusions
In conclusion, this study revealed that MALAT1 was







OR 95% CI P value
(11.1%) 7(38.9%) 0.22 0.05-0.97 0.046
(72.2%) 4(22.2%) 4.89 1.73-13.86 0.003
onths (N = 15) PFS >18 months (N = 18)
(13.3%) 7(38.9%) 0.24 0.05-1.09 0.066
(66.7%) 4(22.2%) 4.38 1.48-12.99 0.008
-cell transplantation; CR, complete response; VGPR, very good partial response;
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http://www.biomedcentral.com/1471-2407/14/809this lncRNA may play a role in the pathogenesis of the
disease. In addition, the change in MALAT1 expression
after treatment was clinically significant and may serve
as a molecular predictor of the patients at risk of early
progression of multiple myeloma.
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